… (OS) and to describe the best tumor response according to the … been observed in early-phase
trials with MEK inhibitors, even … , though no strong biological data have been reported to …

… Few articles combining immunotherapy with biological agents and clearly mentioning the
OBD have been identified (n = 3). For those particular cases, OBD was assessed using …

… whether neoadjuvant toripalimab with or without celecoxib … colorectal cancers, we found the
best estimates of the proportion of … , toripalimab in combination with celecoxib compared with …

… for optimal vaccination dosing and/or for completing the priming and three booster doses. …
shortcoming within this trial, with the αDC1 and CKM showing good biologic function. The low …

… There was no significant change in the time it takes for celecoxib to reach the maximum …
dose of celecoxib and consequently lessen its side effects. RSV and celecoxib combination …

… the optimal biological dose (OBD) based on safety and efficacy. BOIN designs provide a
complete suite for dose finding in early phase trials… of a combination therapy to determine either …

… To this end, the present study examined the biological-effect of PrimeC on exploratory …
study supports the safety and tolerability of a unique combination of ciprofloxacin and celecoxib …

… CXB was optimized and triumphally exploited for determining trace CXB levels existing in
biological … In this regard, some workers have combined physical and chemical traits of various …

… The empiricism involved in determining the ideal “low dose” or OBD and … High-dose celecoxib
and metronomic “Low-dose” … of metronomic celecoxib/fluvastatin combination in pilocytic …

… A phase I trial to determine the optimal biological dose of celecoxib when combined with
erlotinib in advanced non-small cell lung cancer. Clinical cancer research: an official journal of …